Ulrika Simonsson
Professor i farmakokinetik vid Institutionen för farmaceutisk biovetenskap; Forskning; Translationell läkemedelsutveckling; Farmakokinetik och kvantitativ farmakologi
- Telefon:
- 018-471 42 56
- E-post:
- ulrika.simonsson@uu.se
- Besöksadress:
- BMC, Husargatan 3
75124 Uppsala - Postadress:
- Box 591
75124 Uppsala
- Akademiska meriter:
- FarmD, PhD, Professor
Kort presentation
Ulrika Simonsson is a professor in pharmacokinetics, leading her own independent research group focusing on pre-clinical to clinical pharmacokinetic-pharmacodynamic translation and its relation to drug development.
Nyckelord
- antibiotic resistance
- ehealth
- machine learning
- pharmacokinetics
- pharmacometrics
- pharmacodynamics
- therapeutic drug monitoring
- tuberculosis
- translational medicine
- non-linear mixed effects modeling
- modeling and simulation
- artifical intelligence
Biografi
Prof Simonsson is a professor of pharmacokinetics at the Department of Pharmaceutical Biosciences at Uppsala University in Sweden. She holds a Masters in Pharmaceutical Sciences, is a licensed pharmacist and obtained a PhD in Pharmaceutical Sciences from Uppsala University in 2000 focusing on pharmacokinetics and pharmacodynamics. She did her post doc work with Pharsight Coperation, CA, USA in 2001-2002 and was on sabbatical leave during 2004-2006 from her faculty position while working as a pharmacometrician at Astrazeneca. In 2010 she became Associate Professor in Pharmacometrics and full Professor in Pharmacokinetics in 2016. In 2004 she received the AstraZeneca’s Young Talented Scientist award, in 2007 AstraZenceca’s Clinical Innovation award and in 2011, a Grant for Promotion to Professor from Uppsala University.
Her expertise is focused on how modelling and simulation of pharmacokinetics (PK) and pharmacodynamics (PD) can be used to optimize drug development using pharmacometric techniques. She holds large grants within the field of tuberculosis and is currently working within the large consortia ERA4TB and UNIT4TB. Ulrika is currently the supervisor of four PhD students who are doing research within the field of anti-infective drugs. She has supervised ten students to their PhD, five of these as the main supervisor. Ulrika has acted as international opponent at two doctoral thesis, has published more almost 90 peer-reviewed research articles and is routinely giving pharmacometric training to academia and industry. She is board member of CPTR Regulatory Science Consortium, Critical Path to TB Drug Regimens funded by the Critical Path Institute (C-Path), Bill & Melinda Gates Foundation, and the TB Alliance. She has almost 20 years of experience as a pharmacometric external consultant to many drug development companies including regulatory interactions and filing. Her research and consultancy activities have included several different therapeutic areas such as malaria, tuberculosis, HIV, thrombosis/cardiovascular diseases, diabetes, insomnia, prostate cancer, hypertension, asthma and cortisol insuffiency. She has an extensive hands-on experience in modeling complex PKPD and disease models. She has been the pharmacometric lead on two successful registrations and several Phase III filings.
Forskning
Prof Simonsson forskning presenteras på

Publikationer
Senaste publikationer
Risk Factors for COVID-19 and Respiratory Tract Infections during the Coronavirus Pandemic
Ingår i Vaccines, 2024
- DOI för Risk Factors for COVID-19 and Respiratory Tract Infections during the Coronavirus Pandemic
- Ladda ner fulltext (pdf) av Risk Factors for COVID-19 and Respiratory Tract Infections during the Coronavirus Pandemic
Ingår i British Journal of Clinical Pharmacology, s. 1711-1727, 2024
- DOI för Evaluation of critical parameters in the hollow‐fibre system for tuberculosis: A case study of moxifloxacin
- Ladda ner fulltext (pdf) av Evaluation of critical parameters in the hollow‐fibre system for tuberculosis: A case study of moxifloxacin
A noninvasive BCG skin challenge model for assessing tuberculosis vaccine efficacy
Ingår i PLoS biology, 2024
- DOI för A noninvasive BCG skin challenge model for assessing tuberculosis vaccine efficacy
- Ladda ner fulltext (pdf) av A noninvasive BCG skin challenge model for assessing tuberculosis vaccine efficacy
Ingår i Journal of Pharmaceutical Sciences, s. 2895-2903, 2024
- DOI för Model-based interspecies scaling for predicting human pharmacokinetics of CB 4332, a complement factor I protein
- Ladda ner fulltext (pdf) av Model-based interspecies scaling for predicting human pharmacokinetics of CB 4332, a complement factor I protein
Ingår i Clinical Pharmacology and Therapeutics, s. 498-505, 2024
- DOI för Subcutaneous Marzeptacog Alfa (Activated) for On‐Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With Inhibitors
- Ladda ner fulltext (pdf) av Subcutaneous Marzeptacog Alfa (Activated) for On‐Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With Inhibitors
Alla publikationer
Artiklar i tidskrift
Risk Factors for COVID-19 and Respiratory Tract Infections during the Coronavirus Pandemic
Ingår i Vaccines, 2024
- DOI för Risk Factors for COVID-19 and Respiratory Tract Infections during the Coronavirus Pandemic
- Ladda ner fulltext (pdf) av Risk Factors for COVID-19 and Respiratory Tract Infections during the Coronavirus Pandemic
Ingår i British Journal of Clinical Pharmacology, s. 1711-1727, 2024
- DOI för Evaluation of critical parameters in the hollow‐fibre system for tuberculosis: A case study of moxifloxacin
- Ladda ner fulltext (pdf) av Evaluation of critical parameters in the hollow‐fibre system for tuberculosis: A case study of moxifloxacin
A noninvasive BCG skin challenge model for assessing tuberculosis vaccine efficacy
Ingår i PLoS biology, 2024
- DOI för A noninvasive BCG skin challenge model for assessing tuberculosis vaccine efficacy
- Ladda ner fulltext (pdf) av A noninvasive BCG skin challenge model for assessing tuberculosis vaccine efficacy
Ingår i Journal of Pharmaceutical Sciences, s. 2895-2903, 2024
- DOI för Model-based interspecies scaling for predicting human pharmacokinetics of CB 4332, a complement factor I protein
- Ladda ner fulltext (pdf) av Model-based interspecies scaling for predicting human pharmacokinetics of CB 4332, a complement factor I protein
Ingår i Clinical Pharmacology and Therapeutics, s. 498-505, 2024
- DOI för Subcutaneous Marzeptacog Alfa (Activated) for On‐Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With Inhibitors
- Ladda ner fulltext (pdf) av Subcutaneous Marzeptacog Alfa (Activated) for On‐Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With Inhibitors
Ingår i CPT, s. 1250-1261, 2023
- DOI för Seasonal influence on respiratory tract infection severity including COVID-19 quantified through Markov Chain modeling
- Ladda ner fulltext (pdf) av Seasonal influence on respiratory tract infection severity including COVID-19 quantified through Markov Chain modeling
Ingår i Pharmaceuticals, 2023
- DOI för Derivation and Clinical Utility of Safety Targets for Linezolid-Related Adverse Events in Drug-Resistant Tuberculosis Treatment
- Ladda ner fulltext (pdf) av Derivation and Clinical Utility of Safety Targets for Linezolid-Related Adverse Events in Drug-Resistant Tuberculosis Treatment
Ingår i International Journal of Antimicrobial Agents, 2023
- DOI för Model-based analysis of bactericidal activity and a new dosing strategy for optimised-dose rifampicin
- Ladda ner fulltext (pdf) av Model-based analysis of bactericidal activity and a new dosing strategy for optimised-dose rifampicin
Ingår i iScience, 2023
- DOI för Implementing best practices on data generation and reporting of Mycobacterium tuberculosis in vitro assays within the ERA4TB consortium
- Ladda ner fulltext (pdf) av Implementing best practices on data generation and reporting of Mycobacterium tuberculosis in vitro assays within the ERA4TB consortium
Ingår i Frontiers in Pharmacology, 2023
- DOI för Combined quantitative tuberculosis biomarker model for time-to-positivity and colony forming unit to support tuberculosis drug development
- Ladda ner fulltext (pdf) av Combined quantitative tuberculosis biomarker model for time-to-positivity and colony forming unit to support tuberculosis drug development
Ingår i Frontiers in Pharmacology, 2023
- DOI för Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development
- Ladda ner fulltext (pdf) av Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development
Ingår i CPT, s. 977-987, 2023
- DOI för Model-informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategy
- Ladda ner fulltext (pdf) av Model-informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategy
Ingår i Advances in Therapy, s. 3739-3750, 2023
- DOI för Model-Informed Support of Dose Selection for Prophylactic Treatment with Dalcinonacog Alfa in Adult and Paediatric Hemophilia B Patients
- Ladda ner fulltext (pdf) av Model-Informed Support of Dose Selection for Prophylactic Treatment with Dalcinonacog Alfa in Adult and Paediatric Hemophilia B Patients
Cough as Noninvasive Biomarker for Monitoring Tuberculosis Treatment: A Proof-of-Concept Study
Ingår i Annals of the American Thoracic Society, s. 1822-1825, 2023
Reproducibility in pharmacometrics applied in a phase III trial of BCG-vaccination for COVID-19
Ingår i Scientific Reports, 2023
- DOI för Reproducibility in pharmacometrics applied in a phase III trial of BCG-vaccination for COVID-19
- Ladda ner fulltext (pdf) av Reproducibility in pharmacometrics applied in a phase III trial of BCG-vaccination for COVID-19
Clinical standards for the management of adverse effects during treatment for TB
Ingår i The International Journal of Tuberculosis and Lung Disease, s. 506-519, 2023
- DOI för Clinical standards for the management of adverse effects during treatment for TB
- Ladda ner fulltext (pdf) av Clinical standards for the management of adverse effects during treatment for TB
Ingår i eClinicalMedicine, 2022
- DOI för Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double- blind, randomised, controlled, phase 3 trial
- Ladda ner fulltext (pdf) av Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double- blind, randomised, controlled, phase 3 trial
Ingår i CPT, s. 1628-1637, 2022
- DOI för Phase III dose selection of marzeptacog alfa (activated) informed by population pharmacokinetic modeling: A novel hemostatic drug
- Ladda ner fulltext (pdf) av Phase III dose selection of marzeptacog alfa (activated) informed by population pharmacokinetic modeling: A novel hemostatic drug
Ingår i CPT, s. 628-639, 2022
- DOI för A modeling-based proposal for safe and efficacious reintroduction of bedaquiline after dose interruption: A population pharmacokinetics study
- Ladda ner fulltext (pdf) av A modeling-based proposal for safe and efficacious reintroduction of bedaquiline after dose interruption: A population pharmacokinetics study
Model-Informed Precision Dosing of Linezolid in Patients with Drug-Resistant Tuberculosis
Ingår i Pharmaceutics, 2022
- DOI för Model-Informed Precision Dosing of Linezolid in Patients with Drug-Resistant Tuberculosis
- Ladda ner fulltext (pdf) av Model-Informed Precision Dosing of Linezolid in Patients with Drug-Resistant Tuberculosis
Ingår i Pharmaceutics, 2022
- DOI för Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin
- Ladda ner fulltext (pdf) av Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin
Ingår i Journal of Infectious Diseases, s. 1876-1885, 2022
- DOI för Predictive Modeling to Study the Treatment-Shortening Potential of Novel Tuberculosis Drug Regimens, Toward Bundling of Preclinical Data
- Ladda ner fulltext (pdf) av Predictive Modeling to Study the Treatment-Shortening Potential of Novel Tuberculosis Drug Regimens, Toward Bundling of Preclinical Data
Ingår i American Journal of Respiratory and Critical Care Medicine, s. 1228-1235, 2022
Ingår i BMJ Open, 2022
- DOI för Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP)
- Ladda ner fulltext (pdf) av Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP)
Ingår i Clinical Microbiology and Infection, s. 4480-4480000000, 2022
- DOI för Standard therapy of Mycobacterium avium complex pulmonary disease shows limited efficacy in an open source hollow fibre system that simulates human plasma and epithelial lining fluid pharmacokinetics
- Ladda ner fulltext (pdf) av Standard therapy of Mycobacterium avium complex pulmonary disease shows limited efficacy in an open source hollow fibre system that simulates human plasma and epithelial lining fluid pharmacokinetics
Finding the right hazard function for time-to-event modeling: A tutorial and Shiny application
Ingår i CPT, s. 991-1001, 2022
- DOI för Finding the right hazard function for time-to-event modeling: A tutorial and Shiny application
- Ladda ner fulltext (pdf) av Finding the right hazard function for time-to-event modeling: A tutorial and Shiny application
Ingår i BMJ Open, 2022
- DOI för Study protocol for locoregional precision treatment of hepatocellular carcinoma with transarterial chemoembolisation (TACTida), a clinical study: idarubicin dose selection, tissue response and survival
- Ladda ner fulltext (pdf) av Study protocol for locoregional precision treatment of hepatocellular carcinoma with transarterial chemoembolisation (TACTida), a clinical study: idarubicin dose selection, tissue response and survival
Pharmacometrics in tuberculosis: progress and opportunities
Ingår i International Journal of Antimicrobial Agents, 2022
- DOI för Pharmacometrics in tuberculosis: progress and opportunities
- Ladda ner fulltext (pdf) av Pharmacometrics in tuberculosis: progress and opportunities
Ingår i Journal of Infectious Diseases, s. 1039-1047, 2021
Ingår i European Respiratory Journal, 2021
Ingår i Frontiers in Pharmacology, 2020
- DOI för Individualized Dosing With High Inter-Occasion Variability Is Correctly Handled With Model-Informed Precision Dosing: Using Rifampicin as an Example
- Ladda ner fulltext (pdf) av Individualized Dosing With High Inter-Occasion Variability Is Correctly Handled With Model-Informed Precision Dosing: Using Rifampicin as an Example
Ingår i Clinical Pharmacology and Therapeutics, s. 274-286, 2020
- DOI för Translational Model-Informed Approach for Selection of Tuberculosis Drug Combination Regimens in Early Clinical Development.
- Ladda ner fulltext (pdf) av Translational Model-Informed Approach for Selection of Tuberculosis Drug Combination Regimens in Early Clinical Development.
Rifampicin can be given as flat-dosing instead of weight-band dosing
Ingår i Clinical Infectious Diseases, s. 3055-3060, 2020
- DOI för Rifampicin can be given as flat-dosing instead of weight-band dosing
- Ladda ner fulltext (pdf) av Rifampicin can be given as flat-dosing instead of weight-band dosing
Ingår i Applied Sciences, 2020
- DOI för Model-informed drug discovery and development strategy for the rapid development of anti-tuberculosis drug combinations
- Ladda ner fulltext (pdf) av Model-informed drug discovery and development strategy for the rapid development of anti-tuberculosis drug combinations
Ingår i Scientific Reports, 2020
- DOI för Difference in persistent tuberculosis bacteria between in vitro and sputum from patients: implications for translational predictions
- Ladda ner fulltext (pdf) av Difference in persistent tuberculosis bacteria between in vitro and sputum from patients: implications for translational predictions
Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 421-430, 2020
- DOI för A model-based analysis identifies differences in phenotypic resistance between in vitro and in vivo: implications for translational medicine within tuberculosis.
- Ladda ner fulltext (pdf) av A model-based analysis identifies differences in phenotypic resistance between in vitro and in vivo: implications for translational medicine within tuberculosis.
Medical Device Apps: An Introduction to Regulatory Affairs for Developers
Ingår i JMIR mhealth and uhealth, 2020
- DOI för Medical Device Apps: An Introduction to Regulatory Affairs for Developers
- Ladda ner fulltext (pdf) av Medical Device Apps: An Introduction to Regulatory Affairs for Developers
Ingår i Haemophilia, s. 164-172, 2020
Anti‐tuberculosis effect of isoniazid scales accurately from zebrafish to humans
Ingår i British Journal of Pharmacology, s. 5518-5533, 2020
- DOI för Anti‐tuberculosis effect of isoniazid scales accurately from zebrafish to humans
- Ladda ner fulltext (pdf) av Anti‐tuberculosis effect of isoniazid scales accurately from zebrafish to humans
Ingår i Clinical and Translational Science, s. 1060-1064, 2020
- DOI för Quantification of Natural Growth of Two Strains of Mycobacterium Marinum for Translational Antituberculosis Drug Development
- Ladda ner fulltext (pdf) av Quantification of Natural Growth of Two Strains of Mycobacterium Marinum for Translational Antituberculosis Drug Development
Ingår i Clinical Pharmacology and Therapeutics, s. 1285-1289, 2020
Ingår i Antimicrobial Agents and Chemotherapy, 2020
- DOI för Drug Effect of Clofazimine on Persisters Explains an Unexpected Increase in Bacterial Load in Patients
- Ladda ner fulltext (pdf) av Drug Effect of Clofazimine on Persisters Explains an Unexpected Increase in Bacterial Load in Patients
Ingår i Antimicrobial Agents and Chemotherapy, 2019
Individualised dosing algorithm and personalised treatment of high‐dose rifampicin for tuberculosis
Ingår i British Journal of Clinical Pharmacology, s. 2341-2350, 2019
Consider ASCPT in Your End-of-Year Giving
Ingår i Clinical Pharmacology and Therapeutics, s. 17-21, 2019
Ingår i European Journal of Pharmaceutical Sciences, s. 196-203, 2018
Ingår i BMJ Open, 2018
- DOI för Plasma concentrations of second-line antituberculosis drugs in relation to minimum inhibitory concentrations in multidrug-resistant tuberculosis patients in China: a study protocol of a prospective observational cohort study
- Ladda ner fulltext (pdf) av Plasma concentrations of second-line antituberculosis drugs in relation to minimum inhibitory concentrations in multidrug-resistant tuberculosis patients in China: a study protocol of a prospective observational cohort study
Ingår i AAPS Journal, 2018
- DOI för Comparisons of analysis methods for assessment of pharmacodynamic interactions including design recommendations
- Ladda ner fulltext (pdf) av Comparisons of analysis methods for assessment of pharmacodynamic interactions including design recommendations
Improving treatment outcome assessment in a mouse tuberculosis model
Ingår i Scientific Reports, 2018
- DOI för Improving treatment outcome assessment in a mouse tuberculosis model
- Ladda ner fulltext (pdf) av Improving treatment outcome assessment in a mouse tuberculosis model
Ingår i Journal of Antimicrobial Chemotherapy, s. 437-447, 2018
- DOI för A model-informed preclinical approach for prediction of clinical pharmacodynamic interactions of anti-TB drug combinations
- Ladda ner fulltext (pdf) av A model-informed preclinical approach for prediction of clinical pharmacodynamic interactions of anti-TB drug combinations
Ingår i Clinical Pharmacology and Therapeutics, s. 674-683, 2018
- DOI för A Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin Doses
- Ladda ner fulltext (pdf) av A Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin Doses
Ingår i Journal of Infectious Diseases, s. 991-999, 2018
Ingår i Clinical Infectious Diseases, s. 34-41, 2018
- DOI för The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis
- Ladda ner fulltext (pdf) av The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis
Ingår i Journal of Antimicrobial Chemotherapy, s. 2838-2845, 2018
Ingår i Clinical Pharmacology and Therapeutics, s. 1208-1218, 2018
- DOI för Forecasting Clinical Dose-Response From Preclinical Studies in Tuberculosis Research: Translational Predictions With Rifampicin
- Ladda ner fulltext (pdf) av Forecasting Clinical Dose-Response From Preclinical Studies in Tuberculosis Research: Translational Predictions With Rifampicin
Ingår i European Journal of Pharmaceutical Sciences, s. 531-538, 2018
A general pharmacodynamic interaction model identifies perpetrators and victims in drug interactions
Ingår i Nature Communications, 2017
- DOI för A general pharmacodynamic interaction model identifies perpetrators and victims in drug interactions
- Ladda ner fulltext (pdf) av A general pharmacodynamic interaction model identifies perpetrators and victims in drug interactions
Ingår i Frontiers in Veterinary Science, 2017
Ingår i Journal of Antimicrobial Chemotherapy, s. 2311-2319, 2017
- DOI för Improved power for TB Phase IIa trials using a model-based pharmacokinetic-pharmacodynamic approach compared with commonly used analysis methods
- Ladda ner fulltext (pdf) av Improved power for TB Phase IIa trials using a model-based pharmacokinetic-pharmacodynamic approach compared with commonly used analysis methods
Ingår i CPT, s. 787-797, 2017
- DOI för Assessing Pharmacodynamic Interactions in Mice using the Multistate Tuberculosis Pharmacometric and General Pharmacodynamic Interaction Models
- Ladda ner fulltext (pdf) av Assessing Pharmacodynamic Interactions in Mice using the Multistate Tuberculosis Pharmacometric and General Pharmacodynamic Interaction Models
Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 325-333, 2017
Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 133-141, 2017
- DOI för The multistate tuberculosis pharmacometric model: a semi-mechanistic pharmacokinetic-pharmacodynamic model for studying drug effects in an acute tuberculosis mouse model
- Ladda ner fulltext 1 (pdf) av The multistate tuberculosis pharmacometric model: a semi-mechanistic pharmacokinetic-pharmacodynamic model for studying drug effects in an acute tuberculosis mouse model
- Ladda ner fulltext 2 (pdf) av The multistate tuberculosis pharmacometric model: a semi-mechanistic pharmacokinetic-pharmacodynamic model for studying drug effects in an acute tuberculosis mouse model
Ingår i Clinical Pharmacokinetics, s. 1079-1090, 2016
Ingår i Journal of Antimicrobial Chemotherapy, s. 964-974, 2016
- DOI för A multistate tuberculosis pharmacometric model: a framework for studying anti-tubercular drug effects in vitro
- Ladda ner fulltext (pdf) av A multistate tuberculosis pharmacometric model: a framework for studying anti-tubercular drug effects in vitro
Ingår i CPT, s. 222-232, 2016
- DOI för Edoxaban Exposure-Response Analysis and Clinical Utility Index Assessment in Patients With Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
- Ladda ner fulltext (pdf) av Edoxaban Exposure-Response Analysis and Clinical Utility Index Assessment in Patients With Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Ingår i CPT, s. 264-273, 2016
- DOI för Application of the Multistate Tuberculosis Pharmacometric Model in Patients With Rifampicin-Treated Pulmonary Tuberculosis
- Ladda ner fulltext (pdf) av Application of the Multistate Tuberculosis Pharmacometric Model in Patients With Rifampicin-Treated Pulmonary Tuberculosis
Ingår i European Journal of Pharmaceutical Sciences, s. 319-333, 2016
- DOI för Population pharmacokinetics, optimised design and sample size determination for rifampicin, isoniazid, ethambutol and pyrazinamide in the mouse
- Ladda ner fulltext (pdf) av Population pharmacokinetics, optimised design and sample size determination for rifampicin, isoniazid, ethambutol and pyrazinamide in the mouse
Ingår i Pharmaceutical research, s. 1093-1103, 2016
Performance of Nonlinear Mixed Effects Models in the Presence of Informative Dropout
Ingår i AAPS Journal, s. 245-255, 2015
Ingår i European Journal of Pharmaceutical Sciences, s. 78-86, 2015
Ingår i European Journal of Clinical Pharmacology, s. 313-319, 2015
- DOI för A pharmacometric pulmonary model predicting the extent and rate of distribution from plasma to epithelial lining fluid and alveolar cells-using rifampicin as an example
- Ladda ner fulltext (pdf) av A pharmacometric pulmonary model predicting the extent and rate of distribution from plasma to epithelial lining fluid and alveolar cells-using rifampicin as an example
Ingår i Journal of clinical pharmacology, s. 1268-1279, 2015
Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 699-708, 2015
- DOI för Evaluation of optimized bronchoalveolar lavage sampling designs for characterization of pulmonary drug distribution
- Ladda ner fulltext (pdf) av Evaluation of optimized bronchoalveolar lavage sampling designs for characterization of pulmonary drug distribution
Ingår i British Journal of Clinical Pharmacology, s. 1374-1387, 2015
Repeated Time-to-event Analysis of Consecutive Analgesic Events in Postoperative Pain
Ingår i Anesthesiology, s. 1411-1419, 2015
Ingår i Anesthesia and Analgesia, s. 904-913, 2015
Ingår i Antimicrobial Agents and Chemotherapy, s. 503-510, 2014
Ingår i Journal of Antimicrobial Chemotherapy, s. 1339-1349, 2014
Ingår i Antimicrobial Agents and Chemotherapy, s. 7557-7559, 2014
D Optimal Designs for Three Poisson Dose-Response Models
Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 201-211, 2013
Model based design and analysis of phase II HIV-1 trials
Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 487-496, 2013
Ingår i Antimicrobial Agents and Chemotherapy, s. 4164-4171, 2013
Ingår i Journal of Pharmacokinetics and Pharmacodynamics, 2013
Ingår i Antiviral Therapy, s. 25-33, 2012
Ingår i British Journal of Clinical Pharmacology, s. 758-767, 2012
Ingår i Antimicrobial Agents and Chemotherapy, s. 4471-4473, 2012
Ingår i Antimicrobial Agents and Chemotherapy, s. 2091-2098, 2012
Population Pharmacokinetics of Ethambutol in South African Tuberculosis Patients
Ingår i Antimicrobial Agents and Chemotherapy, s. 4230-4237, 2011
Ingår i British Journal of Clinical Pharmacology, s. 899-906, 2011
Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients
Ingår i British Journal of Clinical Pharmacology, s. 51-62, 2011
Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 727-742, 2011
Ingår i European Journal of Clinical Pharmacology, s. 1017-1023, 2010
Ingår i Antimicrobial Agents and Chemotherapy, s. 3390-3394, 2010
An example of optimal phase II design for exposure response modelling
Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 475-491, 2010
Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 243-255, 2010
Ingår i European Journal of Clinical Pharmacology, s. 71-80, 2009
Ingår i Antimicrobial Agents and Chemotherapy, s. 2138-2148, 2008
Ingår i Anesthesiology, s. 495-505, 2008
Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 203-217, 2008
Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects.
Ingår i Fundamental & Clinical Pharmacology, s. 307-316, 2007
Ingår i Journal of clinical pharmacology, s. 1159-1171, 2007
Optimal adaptive design in clinical drug development: a simulation example
Ingår i Journal of clinical pharmacology, s. 1231-1243, 2007
An integrated glucose-insulin model to describe oral glucose tolerance test data in type 2 diabetics
Ingår i Journal of clinical pharmacology, s. 1244-1255, 2007
Ingår i Drug Metabolism And Disposition, s. 1624-1631, 2006
Ingår i Rapid Communications in Mass Spectrometry, s. 463-572, 2006
In vivo and mechanistic evidence of nuclear receptor CAR induction by artemisinin
Ingår i European Journal of Clinical Investigation, s. 647-653, 2006
Ingår i Journal of clinical pharmacology, s. 1204-1211, 2006
Ingår i European Journal of Clinical Pharmacology, s. 727-735, 2006
Ingår i Antimicrobial Agents and Chemotherapy, s. 4429-4436, 2005
Ingår i Journal of Pharmaceutical Sciences, s. 1060-1066, 2005
Ingår i Rapid Communications in Mass Spectrometry, s. 2565-2576, 2004
Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9
Ingår i Clinical Pharmacology and Therapeutics, s. 32-43, 2003
Ingår i Journal of chromatography. B, s. 179-191, 2003
Ingår i Biopharmaceutics & drug disposition, s. 71-85, 2003
Ingår i European Journal of Clinical Pharmacology, s. 339-351, 2002
In vitro evidence for auto-induction of artemisinin metabolism in the rat
Ingår i European journal of drug metabolism and pharmacokinetics, s. 173-178, 2001
Ingår i Drug Metabolism And Disposition, s. 227-232, 1999
Ingår i British Journal of Clinical Pharmacology, s. 669-677, 1999
Quantitative in vivo and in vitro sex differences in artemisinin metabolism in rat
Ingår i Xenobiotica, s. 195-204, 1999
Stereospecific analysis of omeprazole supports artemisinin as a potent inducer of CYP2C19
Ingår i Fundamental & Clinical Pharmacology, s. 671-675, 1999
Ingår i British Journal of Clinical Pharmacology, s. 528-535, 1999
Ingår i Drug Metabolism And Disposition, s. 227-232, 1999
Artemisinin induces omeprazole metabolism in human beings
Ingår i Clinical Pharmacology and Therapeutics, s. 160-167, 1998
Artiklar, forskningsöversikt
Ingår i International Journal of Antimicrobial Agents, 2023
- DOI för Early bactericidal activity studies for pulmonary tuberculosis: A systematic review of methodological aspects
- Ladda ner fulltext (pdf) av Early bactericidal activity studies for pulmonary tuberculosis: A systematic review of methodological aspects
Ingår i Frontiers in Pharmacology, 2022
- DOI för Pharmacokinetics and pharmacodynamics of anti-tuberculosis drugs: An evaluation of in vitro, in vivo methodologies and human studies
- Ladda ner fulltext (pdf) av Pharmacokinetics and pharmacodynamics of anti-tuberculosis drugs: An evaluation of in vitro, in vivo methodologies and human studies
Mobile Health Apps for Improvement of Tuberculosis Treatment: Descriptive Review
Ingår i JMIR mhealth and uhealth, 2020
The implications of model-informed drug discovery and development for tuberculosis
Ingår i Drug Discovery Today, s. 481-486, 2017